PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223432
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223432
Europe acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Europe Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and Rest of Europe) Industry Trends and Forecast to 2030.
Strategic initiatives by major market players
Increasing awareness of leukemia cancer
Market Players
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN
Abbott
Siemens Healthcare GmbH
Merck KGAA
Hologic, Inc.
Agilent Technologies, Inc.
DiaSorin S.p.A.
Illumina, Inc.
BIOMERIEUX
Myriad Genetics, Inc.
Quest Diagnostics Incorporated.
Bio-Rad Laboratories, Inc.
Koninklijke Philips N.V.
BD
Exact Sciences Corporation
Time Medical Holding
PlexBio
MinFound Medical Systems Co., Ltd
Medonica Co. LTD
CANON MEDICAL SYSTEMS CORPORATION